“Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030”

To order this 350+ page report, please visit this To order this 350+ page report, please visit this https://www.rootsanalysis.com/reports/view_document/liquid-biopsy-and-nicd-market/279.html


Key Inclusions

§ A detailed review of the overall landscape of the non-invasive cancer diagnostics market, featuring information on the developers of such products and analyses based on a number of relevant parameters, such as year of establishment, company size, geographical location, current development status of proprietary liquid biopsy test (under development, research use only, and available), type of product (assay kit, software / algorithm and device), type of tumor marker analyzed (CTCs, ctDNA, cfDNA, exosomes, and others), key applications (early diagnosis, treatment selection, patient monitoring and recurrence monitoring), type of analyte used (blood, urine and others) and target cancer indications.

§ An analysis of the various partnerships pertaining to non-invasive cancer diagnostics, which have been established between 2016 and 2019, based on various parameters, such as type of partnership, year of partnership, type of tumor marker, target cancer indications and the most active players.

§ An analysis of the investments made in companies engaged in the development of non-invasive cancer diagnostics, including details of seed financing, venture capital financing, debt financing, grants, and capital raised via IPOs and subsequent public offerings.

§ An analysis of the initiatives of big pharma players, highlighting the key focus areas of such companies and analysis based on various relevant parameters, such as stage of development of their proprietary non-invasive cancer diagnostic test(s), key applications, type of tumor marker and target disease indications.

§ A detailed acquisition target analysis, taking into consideration the historical trend of the activity of the companies that have acquired other firms since 2016, and offering a means for other industry stakeholders to identify potential acquisition targets.

§ Elaborate profiles of the key players engaged in this domain, featuring a brief overview of the company, its financial information (if available), a detailed description of its product portfolio, recent developments and an informed future outlook

§ Informed estimates of the existing market size and the future growth opportunities for non-invasive cancer diagnostics. Based on various parameters, such as number of available / under development products and estimated annual adoption rates, we have provided an informed estimate on the likely evolution of the market over the period 2019-2030.


The report features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

§ Type of Tumor Marker

ctDNA

cfDNA

CTCs

Exosomes

Others



§ Application

Diagnosis / Early Diagnosis

Patient Monitoring

Recurrence Monitoring



§ Target Cancer Indication

Breast Cancer

Lung Cancer


Press Release: Variation 4 (Format 5)


Colorectal Cancer

Prostate Cancer

Bladder Cancer

Melanoma

Gastric Cancer

Pancreatic Cancer

Ovarian Cancer

Others



§ End Users

Hospitals

Research Institutes

Others



§ Key Geographical Regions

North America

Europe


§ Asia-Pacific

§ Rest of the World


The report also features inputs from eminent industry stakeholders, according to whom liquid biopsy has the potential to diagnose cancer at a very early stage by analyzing rare circulating tumour markers, thereby, facilitating appropriate / timely treatment decisions. The report includes detailed transcripts of discussions held with the following experts:

§ Joachim Fluhrer, Founder and Medical Director, Genostics

§ Shibichakravarthy Kannan, Founder and CEO, Theranosis Life Sciences

§ Abizar Lakdawalla, Founder, ProXeom

§ Philippe Nore, CEO and Co-founder, MiNDERA

§ Frank Szczepanski, President and CEO, IVDiagnostics

§ Mark Li, CEO, Resolution Bioscience

§ Brad Walsh, CEO, Minomic International

§ Anton Iliuk, President and Chief Technology Officer, Tymora Analytical Operations

§ Burkhard Jansen, Chief Medical Officer, DermTech

§ Christer Ericsson, Chief Scientific Officer, iCellate Medical

§ Jake Micallef, Chief Scientific Officer, VolitionRx

§ Nathalie Bernard, Marketing Director, OncoDNA

§ Riccardo Razzini, Sales and Marketing Manager, LCM Genect

§ Peter French, Strategic Technology Advisor, Sienna Cancer Diagnostics


To request sample pages, please visit thisTo request sample pages, please visit thishttps://www.rootsanalysis.com/reports/279/request-sample.html


Key Questions Answered

§ What are the prevalent trends within the liquid biopsy market?

§ What are the key applications of liquid biopsy?

§ Apart from liquid biopsy, what are the other novel non-invasive cancer diagnostics?

§ What is the role of big pharma players in the non-invasive cancer diagnostics domain?

§ What are the prevalent financing and investment trends within the liquid biopsy market?

§ What are the most popular cancer indications for which non-invasive diagnostics are being developed?

§ Who are the key service providers for liquid biopsy products?

§ How is the current and future market opportunity likely to be distributed across key market segments?


Press Release: Variation 4 (Format 5)


You may also be interested in the following titles:

Companion Diagnostics

Novel Technologies for Delivery of Proteins

Cancer Biomarkers Market


Contact Us:

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

Gaurav.Chaudhary@rootsanalysis.com

Follow
Cards you may also be interested in
4.7 Star App Store Review!
Cpl.dev***uke
The Communities are great you rarely see anyone get in to an argument :)
king***ing
Love Love LOVE
Download

Select Collections